Nu Skin Enterprises Reports Second Quarter Results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results in line with top-line guidance.

Executive Summary

Q2 2024 vs. Prior-year Quarter

ย 

Revenue

$439.1 million; (12.2)%

  • (4.2)% FX impact or $(21.0) million
  • Rhyz revenue $67.8 million; 32.3%

Earnings Per Share (EPS)

$(2.38) or $0.21 excluding restructuring and impairment charges, compared to $0.54

Customers

893,514; (14)%

Paid Affiliates

155,486; (17)% or (9)% excluding an adjustment to eligibility requirements

Sales Leaders

38,592; (16)%

โ€œWe are pleased with our progress as we perform to plan on our transformational efforts, and we are on track as evidenced by our second quarter results,โ€ said Ryan Napierski, Nu Skin president and CEO. โ€œOur revenue was in-line with our expectations despite a 4 percent FX headwind, while adjusted earnings per share slightly exceeded our projections due to heightened operational discipline, excluding our restructuring and impairment charges. As our core Nu Skin business continues to navigate the macro-economic environment, we were encouraged by sequential gains in several of our markets including the U.S. and most of Southeast Asia/Pacific. Additionally, our Rhyz business grew 32 percent versus the prior-year quarter led by strong performances in our Mavely affiliate platform and manufacturing companies.

โ€œWe are intensifying our transformation efforts to become a leading integrated beauty, wellness and lifestyle ecosystem by building synergistic value between our Nu Skin core and Rhyz. In late July, we held our first Western market, in-person affiliate event in over five years with a similar event for Eastern markets coming in September. At the event, we were able to drive energy and alignment among our leaders as we previewed our MYND360 cognitive health division and promoted new activation efforts to grow our salesforce. We also announced plans for a Nu Skin/Mavely app, with Mavelyโ€™s more than 1,200 brands and 70,000 everyday influencers, for our Nu Skin affiliates, anticipated for second-half introduction in the U.S.

โ€œWe are enhancing our developing market strategy including a revised business model, targeted product offering and streamlined operating infrastructure beginning with Latin America and parts of Southeast Asia in the second half. In addition, we are intensifying our plans to enter India with a proprietary business model that will be a catalyst for expansion into other emerging markets. We are also exploring integrated brand building initiatives, including digital marketing and third-party marketplaces, as we strive to be wherever our customers seek to find us.โ€

Q2 2024 Year-over-year Operating Results

ย 

Revenue

$439.1 million compared to $500.3 million

  • (4.2)% FX impact or $(21.0) million
  • Rhyz revenue $67.8 million; +32.3%

ย 

Gross Margin

70.0% compared to 72.9%

  • Nu Skin business was 76.1% compared to 77.2%ย 

ย 

Selling Expenses

37.7% compared to 37.0%

  • Nu Skin business was 42.2% compared to 40.2%ย 

ย 

G&A Expenses

26.9% compared to 27.4%

Operating Margin

(28.6)% or 5.4% excluding restructuring and impairment charges compared to 8.5%

Interest Expense

$6.7 million compared to $5.8 million

Other Income/(Expense)

$0.6 million compared to $0.4 million

Income Tax Rate

10.2% or 41.4% excluding restructuring and impairment charges compared to 27.5%

EPS

$(2.38) or $0.21 excluding restructuring and impairment charges compared to $0.54

ย 

Stockholder Value

ย 

Dividend Payments

$3.0 million

Stock Repurchases

$0.0 million

  • $162.4 million remaining in authorizationย 

ย 

Q3 and Full-year 2024 Outlook

ย 

Q3 2024 Revenue

$430 to $465 million; (14)% to (7)%

  • Approximately (4) to (3)% FX impactย 

ย 

Q3 2024 EPS

$0.08 to $0.18 or $0.15 to $0.25 non-GAAP

2024 Revenue

$1.73 to $1.81 billion; (12)% to (8)%

  • Approximately (4) to (3)% FX impactย 

ย 

2024 EPS

$(2.01) to $(1.81) or $0.75 to $0.95 non-GAAP

โ€œAs we continue to refine our operating model during our transformation, we remain diligent in pursuing cost saving initiatives going forward, including additional product portfolio optimization along with expense management,โ€ said James D. Thomas, chief financial officer. โ€œWe remain on track with our cost efficiency program as reflected by our reductions in G&A expense, helping to protect profitability despite revenue pressures. During the quarter, we generated $51.2 million in cash from operations, reduced inventory levels and paid down debt to strengthen our balance sheet. We also performed an impairment analysis and recorded a $141 million non-cash charge for impairment of goodwill and other intangibles as a result of the decline in stock price and current market conditions.

โ€œGiven that we have performed in-line with expectations for the first half of the year while also considering the increasing FX headwind, we believe it prudent to narrow our annual revenue guidance range. We are now projecting 2024 revenue in the $1.73 to $1.81 billion range, with earnings of $(2.01) to $(1.81) or $0.75 to $0.95 excluding restructuring and impairment charges. Our Q3 guidance assumes continued sequential improvement with projected revenue of $430 to $465 million and earnings per share of $0.08 to $0.18 or $0.15 to $0.25 excluding restructuring and impairment charges.โ€

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 22, 2024.

About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the companyโ€™s products help people look, feel and live their best with brands including Nu Skinยฎ personal care, Pharmanexยฎ nutrition and ageLOCยฎ anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the companyโ€™s current expectations and beliefs. All statements other than statements of historical fact are โ€œforward-looking statementsโ€ for purposes of federal and state securities laws and include, but are not limited to, statements of managementโ€™s expectations regarding the macro environment and the companyโ€™s performance, growth and growth opportunities, strategies, sales force, shareholder value, product previews and launches, product portfolio optimization, transformation, evolution, operational and financial initiatives, digital tools and initiatives, new market expansion, and plans for developing and emerging markets; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as โ€œbelieve,โ€ โ€œexpect,โ€ โ€œanticipate,โ€ โ€œbecome,โ€ โ€œโ€plan,โ€ accelerate,โ€ โ€œproject,โ€ โ€œcontinue,โ€ โ€œoutlook,โ€ โ€œguidance,โ€ โ€œimprove,โ€ โ€œwill,โ€ โ€œwould,โ€ โ€œcould,โ€ โ€œmay,โ€ โ€œmight,โ€ the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

  • any failure of current or planned initiatives or products to generate interest among the companyโ€™s sales force and customers and generate sponsoring and selling activities on a sustained basis;
  • risk that direct selling laws and regulations in any of the companyโ€™s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the companyโ€™s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
  • economic conditions and events globally;
  • competitive pressures in the companyโ€™s markets;
  • risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
  • adverse publicity related to the companyโ€™s business, products, industry or any legal actions or complaints by the companyโ€™s sales force or others;
  • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
  • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
  • risk of foreign-currency fluctuations and the currency translation impact on the companyโ€™s business associated with these fluctuations;
  • uncertainties regarding the future financial performance of the businesses the company has acquired;
  • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
  • regulatory risks associated with the companyโ€™s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and
  • the companyโ€™s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the companyโ€™s products imported into the companyโ€™s markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the companyโ€™s various markets.

The companyโ€™s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the companyโ€™s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the companyโ€™s performance. It is calculated by translating the current periodโ€™s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year periodโ€™s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the companyโ€™s revenue from period to period.

Earnings per share, operating margin and income tax rate, each excluding restructuring and impairment charges, also are non-GAAP financial measures. Restructuring and impairment charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the companyโ€™s performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended June 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

Three Months Ended June 30,

ย 

ย 

Constant-Currency

ย 

2024

ย 

ย 

2023

ย 

Change

ย 

Change

Nu Skin

Americas

$

84,935

ย 

ย 

$

107,641

ย 

ย 

(21.1

)%

ย 

(15.1

)%

Mainland China

ย 

64,710

ย 

ย 

88,362

ย 

ย 

(26.8

)%

ย 

(24.5

)%

Southeast Asia/Pacific

ย 

60,341

ย 

ย 

ย 

63,764

ย 

ย 

(5.4

)%

ย 

(0.5

)%

Japan

ย 

42,587

ย 

ย 

ย 

50,862

ย 

ย 

(16.3

)%

ย 

(4.9

)%

South Korea

ย 

44,119

ย 

ย 

ย 

53,686

ย 

ย 

(17.8

)%

ย 

ย 

(14.3

)%

Europe & Africa

ย 

40,714

ย 

ย 

ย 

46,968

ย 

ย 

(13.3

)%

ย 

(12.3

)%

Hong Kong/Taiwan

ย 

33,846

ย 

ย 

ย 

37,108

ย 

ย 

(8.8

)%

ย 

(5.5

)%

Nu Skin other

ย 

(4

)

ย 

ย 

597

ย 

ย 

(100.7

)%

ย 

ย 

(100.8

)%

Total Nu Skin

371,248

ย 

448,988

(17.3

)%

(12.6

)%

Rhyz Investments

Manufacturing

51,473

ย 

45,551

13.0

%

13.0

%

Rhyz other

16,360

ย 

5,718

186.1

%

186.1

%

Total Rhyz Investments

67,833

ย 

51,269

32.3

%

32.3

%

Total

$

439,081

ย 

ย 

$

500,257

ย 

ย 

(12.2

)%

ย 

(8.0

)%

The following table sets forth revenue for the six-month periods ended June 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

Six Months Ended June 30,

ย 

ย 

Constant-Currency

ย 

2024

ย 

2023

ย 

Change

ย 

Change

Nu Skin

Americas

$

159,966

ย 

$

208,798

ย 

ย 

(23.4

)%

ย 

(17.5

)%

Mainland China

ย 

125,777

ย 

156,338

ย 

ย 

(19.5

)%

ย 

(16.5

)%

Southeast Asia/Pacific

ย 

120,406

ย 

ย 

131,574

ย 

ย 

(8.5

)%

ย 

(4.4

)%

Japan

ย 

86,823

ย 

ย 

103,468

ย 

ย 

(16.1

)%

ย 

(5.3

)%

South Korea

ย 

85,082

ย 

ย 

124,010

ย 

ย 

(31.4

)%

ย 

ย 

(28.5

)%

Europe & Africa

ย 

82,987

ย 

ย 

94,412

ย 

ย 

(12.1

)%

ย 

(12.1

)%

Hong Kong/Taiwan

ย 

64,312

ย 

ย 

71,656

ย 

ย 

(10.2

)%

ย 

(7.6

)%

Nu Skin other

ย 

668

ย 

ย 

482

ย 

ย 

38.6

%

ย 

ย 

38.6

%

Total Nu Skin

726,021

890,738

(18.5

)%

(14.1

)%

Rhyz Investments

Manufacturing

101,775

81,318

25.2

%

25.2

%

Rhyz other

28,591

9,663

195.9

%

195.9

%

Total Rhyz Investments

130,366

90,981

43.3

%

43.3

%

Total

$

856,387

ย 

$

981,719

ย 

ย 

(12.8

)%

ย 

(8.8

)%

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2024, and 2023:

Three Months Ended

June 30,

2024

ย 

2023

Change

Customers

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Americas

ย 

226,626

263,138

(14)%

Mainland China

ย 

179,021

214,907

(17)%

Southeast Asia/Pacific

ย 

88,662

106,283

(17)%

Japan

ย 

109,357

112,484

ย 

(3)%

South Korea

ย 

99,358

112,019

(11)%

Europe & Africa

ย 

143,336

177,472

(19)%

Hong Kong/Taiwan

ย 

47,154

54,815

(14)%

Total Customers

893,514

1,041,118

(14)%

Paid Affiliates

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Americas

ย 

29,531

36,048

(18)%

Mainland China

ย 

24,404

28,825

(15)%

Southeast Asia/Pacific(1)

ย 

29,701

32,769

(9)%

Japan(1)

ย 

21,575

36,765

(41)%

South Korea

ย 

22,116

23,012

(4)%

Europe & Africa

ย 

17,402

19,906

(13)%

Hong Kong/Taiwan

ย 

10,757

10,327

4%

Total Paid Affiliates

155,486

187,652

(17)%

Sales Leaders

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Americas

ย 

6,070

7,872

(23)%

Mainland China

10,266

13,777

(25)%

Southeast Asia/Pacific

ย 

5,601

5,814

(4)%

Japan

ย 

6,116

5,853

4%

South Korea

ย 

4,689

5,784

(19)%

Europe & Africa

ย 

3,432

4,105

(16)%

Hong Kong/Taiwan

ย 

2,418

2,602

(7)%

Total Sales Leaders

38,592

45,807

(16)%

(1) The June 30, 2024, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters.

  • โ€œCustomersโ€ are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
  • โ€œPaid Affiliatesโ€ are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as โ€œBrand Affiliatesโ€ because their primary role is to promote our brand and products through their personal social networks.
  • โ€œSales Leadersโ€ are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

ย 

ย 

ย 

ย 

ย 

Three Months Ended

June 30,

ย 

Six Months Ended

June 30,

ย 

2024

ย 

ย 

2023

ย 

2024

ย 

ย 

2023

Revenue

$

439,081

ย 

ย 

$

500,257

ย 

$

856,387

ย 

ย 

$

981,719

Cost of sales

ย 

131,904

ย 

ย 

ย 

135,542

ย 

ย 

255,146

ย 

ย 

ย 

269,130

Gross profit

ย 

307,177

ย 

ย 

ย 

364,715

ย 

ย 

601,241

ย 

ย 

ย 

712,589

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Operating expenses:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Selling expenses

ย 

165,463

ย 

ย 

ย 

185,165

ย 

ย 

319,005

ย 

ย 

ย 

373,289

General and administrative expenses

ย 

117,921

ย 

ย 

ย 

137,044

ย 

ย 

242,487

ย 

ย 

ย 

270,943

Restructuring and impairment expenses

149,350

ย 

โ€”

156,484

ย 

9,787

Total operating expenses

ย 

432,734

ย 

ย 

ย 

322,209

ย 

ย 

717,976

ย 

ย 

ย 

654,019

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Operating income (loss)

ย 

(125,557

)

ย 

ย 

42,506

ย 

ย 

(116,735

)

ย 

ย 

58,570

Interest expense

ย 

6,720

ย 

ย 

ย 

5,769

ย 

ย 

14,045

ย 

ย 

ย 

10,657

Other expense, net

ย 

629

ย 

ย 

ย 

376

ย 

ย 

233

ย 

ย 

ย 

3,788

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Income (loss) before provision for income taxes

ย 

(131,648

)

ย 

ย 

37,113

ย 

ย 

(130,547

)

ย 

ย 

51,701

Provision (benefit) for income taxes

ย 

(13,390

)

ย 

ย 

10,221

ย 

ย 

(11,756

)

ย 

ย 

13,433

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Net income (loss)

$

(118,258

)

ย 

$

26,892

ย 

$

(118,791

)

ย 

$

38,268

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Net income (loss) per share:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Basic

$

(2.38

)

ย 

$

0.54

ย 

$

(2.39

)

ย 

$

0.77

Diluted

$

(2.38

)

ย 

$

0.54

ย 

$

(2.39

)

ย 

$

0.76

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Weighted-average common shares outstanding (000s):

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Basic

ย 

49,688

ย 

ย 

ย 

49,931

ย 

ย 

49,613

ย 

ย 

ย 

49,789

Diluted

ย 

49,688

ย 

ย 

ย 

50,161

ย 

ย 

49,613

ย 

ย 

ย 

50,098

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

ย 

ย 

ย 

ย 

ย 

June 30,

2024

ย 

December 31,

2023

ASSETS

ย 

ย 

ย 

Current assets:

ย 

ย 

ย 

Cash and cash equivalents

$

224,250

ย 

ย 

$

256,057

ย 

Current investments

ย 

8,671

ย 

ย 

ย 

11,759

ย 

Accounts receivable, net

ย 

71,554

ย 

ย 

ย 

72,879

ย 

Inventories, net

ย 

243,994

ย 

ย 

ย 

279,978

ย 

Prepaid expenses and other

ย 

105,937

ย 

ย 

ย 

81,198

ย 

Total current assets

ย 

654,406

ย 

ย 

ย 

701,871

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Property and equipment, net

ย 

411,918

ย 

ย 

ย 

432,965

ย 

Operating lease right-of-use assets

88,071

ย 

90,107

ย 

Goodwill

ย 

99,885

ย 

ย 

ย 

230,768

ย 

Other intangible assets, net

ย 

88,464

ย 

ย 

ย 

105,309

ย 

Other assets

ย 

243,228

ย 

ย 

ย 

245,443

ย 

Total assets

$

1,585,972

ย 

ย 

$

1,806,463

ย 

ย 

ย 

ย 

ย 

ย 

ย 

LIABILITIES AND STOCKHOLDERSโ€™ EQUITY

ย 

ย 

ย 

ย 

ย 

Current liabilities:

ย 

ย 

ย 

ย 

ย 

Accounts payable

$

36,305

ย 

ย 

$

43,505

ย 

Accrued expenses

ย 

242,288

ย 

ย 

ย 

260,366

ย 

Current portion of long-term debt

ย 

30,000

ย 

ย 

ย 

25,000

ย 

Total current liabilities

ย 

308,593

ย 

ย 

ย 

328,871

ย 

ย 

Operating lease liabilities

ย 

70,318

ย 

ย 

ย 

70,943

ย 

Long-term debt

ย 

428,327

ย 

ย 

ย 

478,040

ย 

Other liabilities

ย 

92,570

ย 

ย 

ย 

106,641

ย 

Total liabilities

ย 

899,808

ย 

ย 

ย 

984,495

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Commitments and contingencies

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Stockholdersโ€™ equity:

ย 

ย 

ย 

ย 

ย 

Class A common stock โ€“ 500 million shares authorized, $0.001 par value, 90.6 million shares issued

ย 

91

ย 

ย 

ย 

91

ย 

Additional paid-in capital

ย 

621,440

ย 

ย 

ย 

621,853

ย 

Treasury stock, at cost โ€“ 40.9 million and 41.1 million shares

ย 

(1,564,090

)

ย 

ย 

(1,570,440

)

Accumulated other comprehensive loss

ย 

(116,995

)

ย 

ย 

(100,006

)

Retained earnings

ย 

1,745,718

ย 

ย 

ย 

1,870,470

ย 

Total stockholders' equity

ย 

686,164

ย 

ย 

ย 

821,968

ย 

Total liabilities and stockholdersโ€™ equity

$

1,585,972

ย 

ย 

$

1,806,463

ย 

NU SKIN ENTERPRISES, INC.

Reconciliation of Operating Margin Excluding Impact of Restructuring and Impairment to GAAP Operating Margin

(in thousands, except for per share amounts)

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Three months ended

June 30,

ย 

Six months ended

June 30,

ย 

ย 

2024

ย 

ย 

2023

ย 

ย 

2024

ย 

ย 

2023

ย 

Operating Income

ย 

$

(125,557

)

ย 

$

42,506

ย 

ย 

$

(116,735

)

ย 

$

58,570

ย 

Impact of restructuring and impairment:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Restructuring and impairment

ย 

ย 

149,350

ย 

ย 

ย 

-

ย 

ย 

ย 

156,484

ย 

ย 

ย 

9,787

ย 

Adjusted operating income

ย 

$

23,793

ย 

ย 

$

42,506

ย 

ย 

$

39,749

ย 

ย 

$

68,357

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Operating margin

ย 

ย 

(28.6

)%

ย 

ย 

8.5

%

ย 

ย 

(13.6

)%

ย 

ย 

6.0

%

Operating margin, excluding restructuring impact

ย 

ย 

5.4

%

ย 

ย 

8.5

%

ย 

ย 

4.6

%

ย 

ย 

7.0

%

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Revenue

ย 

$

439,081

ย 

ย 

$

500,257

ย 

ย 

$

856,387

ย 

ย 

$

981,719

ย 

NU SKIN ENTERPRISES, INC.

Reconciliation of Effective Tax Rate Excluding Impact of Restructuring and Impairment to GAAP Effective Tax Rate

(in thousands, except for per share amounts)

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Three months ended

June 30,

ย 

Six months ended

June 30,

ย 

ย 

2024

ย 

ย 

2023

ย 

ย 

2024

ย 

ย 

2023

ย 

Provision (benefit) for income taxes

ย 

$

(13,390

)

ย 

$

10,221

ย 

ย 

$

(11,756

)

ย 

$

13,433

ย 

Impact of restructuring and impairment on provision for income taxes

ย 

ย 

20,715

ย 

ย 

ย 

-

ย 

ย 

ย 

23,071

ย 

ย 

ย 

2,593

ย 

Provision for income taxes, excluding impact of restructuring and impairment

ย 

$

7,325

ย 

ย 

$

10,221

ย 

ย 

$

11,315

ย 

ย 

$

16,026

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Income before provision for income taxes

ย 

ย 

(131,648

)

ย 

ย 

37,113

ย 

ย 

ย 

(130,547

)

ย 

ย 

51,701

ย 

Impact of restructuring and impairment expense:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Restructuring and impairment

ย 

ย 

149,350

ย 

ย 

ย 

-

ย 

ย 

ย 

156,484

ย 

ย 

ย 

9,787

ย 

Income before provision for income taxes, excluding impact of restructuring and impairment

ย 

$

17,702

ย 

ย 

$

37,113

ย 

ย 

$

25,937

ย 

ย 

$

61,488

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Effective tax rate

ย 

ย 

10.2

%

ย 

ย 

27.5

%

ย 

ย 

9.0

%

ย 

ย 

26.0

%

Effective tax rate, excluding restructuring and impairment impact

ย 

ย 

41.4

%

ย 

ย 

27.5

%

ย 

ย 

43.6

%

ย 

ย 

26.1

%

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share

(in thousands, except for per share amounts)

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Three months ended

June 30,

ย 

Six months ended

June 30,

ย 

ย 

2024

ย 

ย 

2023

ย 

2024

ย 

ย 

2023

ย 

Net income

ย 

$

(118,258

)

ย 

$

26,892

ย 

$

(118,791

)

ย 

$

38,268

ย 

Impact of restructuring and impairment expense:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Restructuring and impairment

ย 

ย 

149,350

ย 

ย 

ย 

-

ย 

ย 

156,484

ย 

ย 

ย 

9,787

ย 

Tax impact

ย 

ย 

(20,715

)

ย 

ย 

-

ย 

ย 

(23,071

)

ย 

ย 

(2,593

)

Adjusted net income

ย 

$

10,377

ย 

ย 

$

26,892

ย 

$

14,622

ย 

ย 

$

45,462

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Diluted earnings per share

ย 

$

(2.38

)

ย 

$

0.54

ย 

$

(2.39

)

ย 

$

0.76

ย 

Diluted earnings per share, excluding restructuring impact

ย 

$

0.21

ย 

ย 

$

0.54

ย 

$

0.29

ย 

ย 

$

0.91

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Weighted-average common shares outstanding (000)

ย 

ย 

49,688

ย 

ย 

ย 

50,161

ย 

ย 

49,613

ย 

ย 

ย 

50,098

ย 

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Three months ended

September 30, 2024

ย 

Year ended December 31, 2024

ย 

ย 

Low end

ย 

High end

ย 

Low end

ย 

High end

Earnings Per Share

ย 

$

0.08

ย 

ย 

$

0.18

ย 

ย 

$

(2.01

)

ย 

$

(1.81

)

Impact of restructuring and impairment expense:

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

Restructuring and impairment

ย 

ย 

0.10

ย 

ย 

ย 

0.10

ย 

ย 

ย 

3.25

ย 

ย 

ย 

3.25

ย 

Tax impact

ย 

ย 

(0.03

)

ย 

ย 

(0.03

)

ย 

ย 

(0.50

)

ย 

ย 

(0.50

)

Adjusted EPS

ย 

$

0.15

ย 

ย 

$

0.25

ย 

ย 

$

0.75

ย 

ย 

$

0.95

ย 

ย 

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.36
+5.45 (2.18%)
AAPL  273.17
+7.00 (2.63%)
AMD  303.46
+18.97 (6.67%)
BAC  53.12
-0.36 (-0.67%)
GOOG  337.73
+7.26 (2.20%)
META  674.72
+5.88 (0.88%)
MSFT  432.92
+8.76 (2.07%)
NVDA  202.50
+2.62 (1.31%)
ORCL  187.50
+6.33 (3.49%)
TSLA  387.51
+1.09 (0.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gift this article